Fda Priority Review News Today

French drug major Sanofi (SNYNF, SNY) announced Friday that the U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application or sBLA for Dupixent (dupilumab).

Keytruda plus chemotherapy has been granted a priority review by the FDA to treat certain patients with endometrial cancer.

The Food and Drug Administration is reviewing the novel drug, linvoseltamab, for the treatment of patients with pretreated, relapsed or refractory multiple myeloma.

The FDA has granted priority review to a new drug application seeking the approval of the optical imaging agent Lumisight for use in patients with breast cancer, according to an announcement from Lumicell, Inc.

The world’s first therapy for rare disease Niemann-Pick types A/B and B has surfaced in Japan, courtesy of Sanofi.